Oxidative Medicine and Cellular Longevity / 2018 / Article / Tab 1

Research Article

Long-Term Resveratrol Supplementation as a Secondary Prophylaxis for Stroke

Table 1

Demographic and clinical characteristics.

CharacteristicsResveratrol 100 mg group
()
Resveratrol 200 mg group
()
Control group
()
Number%Number%Number%

Gender
Females3239.512138.183740.22
Males4960.493461.825559.78
Age
55–60 years44.9423.6355.43
61–65 years5466.673563.645964.13
>65 years2328.391832.732830.44
Average65.03 ± 8.2464.52 ± 8.0564.78 ± 6.32
Risk factors
Obesity3138.272138.183942.39
Toxicants (coffee, tobacco, and alcohol)3745.682341.824245.65
Stress4150.622952.734751.09
HBP6479.014378.187278.26
Diabetes1214.63916.361415.22
Dyslipidemia5061.733767.36166.30
Diagnostic
Ischemic stroke5972.644174.546873.91
Hemorrhagic stroke2227.161425.462426.09
Time since stroke occurred
<3 months1012.35712.731111.96
3–6 months4656.793054.545054.35
6–12 months2530.861832.733133.70
Average (months)5.08 ± 1.225.13 ± 1.145.17 ± 1.16

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.